SIX1 and esophageal cancer: SIX1 has been reported to increase CSC numbers in vitro and in vivo: SIX1 increased phenotypic and functional CSCs in breast [17], colorectal [18] and esophageal cancer [19] and phenotypic CSCs in pancreatic cancers [20].